SER on NYSE

Serina Therapeutics, Inc.

We are a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and other indications.3 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with CNBX Pharmaceuticals Inc., SOLIGENIX, INC. or BullFrog AI Holdings, Inc., or pick any stock.

  • TickerSER on NYSE1
  • IndustryPharmaceutical Preparations1
  • HeadquartersHuntsville, Alabama1
  • Incorporated inAL2
  • Business address601 Genome Way, Suite 2001, Huntsville, Al 358062
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

We are a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and other indications. Our POZ drug delivery technology is designed to enable certain existing drugs and novel drug candidates to be modified in a way that provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs).The Company’s proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline) and is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via easy-to-administer, long-acting subcutaneous injection.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-18478.5%Operating margin4
-14755.4%Net margin4
132.1%Revenue growth, 20254
-$18.0MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development100¢$13.2M
  • Income tax0¢$18.0K

Out of $130.0K in revenue.4 The company lost money this year.

Financial statements

Revenue567894$130.0K in 2025−92% since 2019
0$1.0M$2.0M$3.0M$4.0M2019: $1.7M$1.7M20192020: $361.0K$361.0K2020−79%2021: $144.0K$144.0K2021−60%2022: $34.0K$34.0K2022−76%2023: $3.2M$3.2M2023+9174%2024: $56.0K$56.0K2024−98%2025: $130.0K$130.0K2025+132%
Gross profit5678$102.0K in 2023−93% since 2019
0$500.0K$1.0M$1.5M2019: $1.5M$1.5M20192020: $335.0K$335.0K2020−77%2021: $125.0K$125.0K2021−63%2022: $21.0K$21.0K2022−83%2023: $102.0K$102.0K2023+386%
Operating income567894-$24.0M in 2025+91% since 2019
-$30.0M-$20.0M-$10.0M02019: -$12.6M-$12.6M20192020: -$10.1M-$10.1M2020−20%2021: -$7.9M-$7.9M2021−21%2022: -$7.0M-$7.0M2022−12%2023: -$3.1M-$3.1M2023−55%2024: -$17.0M-$17.0M2024+445%2025: -$24.0M-$24.0M2025+41%
Net income567894-$19.2M in 2025+58% since 2019
-$20.0M-$10.0M0$10.0M2019: -$12.2M-$12.2M20192020: -$10.9M-$10.9M2020−11%2021: -$8.7M-$8.7M2021−20%2022: -$10.5M-$10.5M2022+21%2023: $5.3M$5.3M20232024: -$11.1M-$11.1M20242025: -$19.2M-$19.2M2025+72%
Fiscal year2019202020212022202320242025
Revenue$1.7M5$361.0K6$144.0K7$34.0K8$3.2M9$56.0K4$130.0K4
Cost of revenue$244.0K5$26.0K6$19.0K7$13.0K8$40.0K8
Gross profit$1.5M5$335.0K6$125.0K7$21.0K8$102.0K8
Research and development$5.9M5$3.7M6$1.5M7$1.0M8$2.4M9$7.5M4$13.2M4
Operating expenses$8.2M7$7.0M8$6.3M9$17.1M4$24.2M4
Operating income-$12.6M5-$10.1M6-$7.9M7-$7.0M8-$3.1M9-$17.0M4-$24.0M4
Interest$1.1M7$3.3M8$4.9M8
Income before tax$8.7M7$10.5M8$5.3M9-$11.2M4-$19.2M4
Income tax$148.0K5-$150.0K6$09$04$18.0K4
Net income-$12.2M5-$10.9M6-$8.7M7-$10.5M8$5.3M9-$11.1M4-$19.2M4
Earnings per share-$0.237-$9.708$2.369-$1.514-$1.914
Earnings per share (diluted)-$9.708$0.739-$1.514-$1.914
Shares (weighted, basic)37.9M shares71.1K shares82.2M shares97.4M shares410.2M shares4
Shares (weighted, diluted)1.1K shares87.4M shares97.4M shares410.2M shares4

Compare Serina Therapeutics, Inc. with another company

Leadership

Who has led Serina Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Steven A. Ledger2024–now

Chief financial officer

  1. Russell Skibsted2018–2019
  2. Andrea Eun Jae Park2020–2021
  3. Gregory S. Curhan2024–now

Chief operating officer

  1. Nafees Naseer Malik2018–2021
  2. Tacey Viegas2024
20202025
Board members and other officers (21)

Former names

  • AgeX Therapeutics, Inc.Jul 10, 2017 to Apr 1, 20242

Timeline

  1. Apr 3, 2024New chief executive Steven A. Ledger becomes CEO12

Filings

359 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 111 major events, 127 insider forms, 30 large holders, 70 other. The latest 20:

  1. Oct 9, 20268-K EDGAR
  2. Sep 9, 20268-K EDGAR
  3. Aug 31, 2026EFFECT EDGAR
  4. Aug 27, 20268-K EDGAR
  5. Aug 24, 2026S-1 EDGAR
  6. Aug 13, 20268-K EDGAR
  7. Aug 13, 202610-Q EDGAR
  8. Aug 13, 2026S-8 EDGAR
  9. Jul 23, 20264 EDGAR
  10. Jul 23, 20263 EDGAR
  11. Jul 23, 20268-K EDGAR
  12. Jul 22, 20268-K EDGAR
  13. Jul 22, 2026SCHEDULE 13D/A EDGAR
  14. Jul 9, 20264 EDGAR
  15. Jun 24, 20268-K EDGAR
  16. Jun 22, 20264 EDGAR
  17. Jun 22, 20264 EDGAR
  18. Jun 22, 20264 EDGAR
  19. Jun 22, 20264 EDGAR
  20. Jun 22, 20264 EDGAR

The 359 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

71 open-market trades by officers, directors and large owners since October 2021: 30 buys and 41 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 7, 2026Brannan Stephen K.DirectorBuy1,000$2.03$2.0KForm 4
Jun 12, 2026WILSON KAREN JDirectorBuy5,000$1.77$8.8KForm 4
Jun 11, 2026WILSON KAREN JDirectorBuy5,100$1.75$8.9KForm 4
May 22, 2026Venkatesan JayDirectorBuy589$1.78$1.0KForm 4
May 22, 2026WILSON KAREN JDirectorBuy10,000$1.93$19.3KForm 4
May 21, 2026WILSON KAREN JDirectorBuy10,000$1.77$17.7KForm 4
May 19, 2026Marshall Richard PeterDirectorBuy12,183$1.65$20.1KForm 4
Mar 23, 2026Moreadith RandallChief Scientific OfficerSale6,500$2.86$18.6KForm 4
Mar 19, 2026Moreadith RandallChief Scientific OfficerSale39,000$2.50$97.5KForm 4
Feb 2, 2026Moreadith RandallChief Scientific OfficerSale6,500$3.03$19.7KForm 4
Jan 28, 2026Moreadith RandallChief Scientific OfficerSale6,500$3.57$23.2KForm 4
Jan 22, 2026Moreadith RandallChief Scientific OfficerSale2,500$2.95$7.4KForm 4
Jan 21, 2026Moreadith RandallChief Scientific OfficerSale2,000$3.00$6.0KForm 4
Jan 20, 2026Moreadith RandallChief Scientific OfficerSale2,000$3.07$6.1KForm 4
Jan 14, 2026Moreadith RandallChief Scientific OfficerSale1,084$2.50$2.7KForm 4
Jan 13, 2026Moreadith RandallChief Scientific OfficerSale5,416$2.50$13.5KForm 4
Jan 8, 2026Moreadith RandallChief Scientific OfficerSale13,000$2.69$35.0KForm 4
Dec 23, 2025Moreadith RandallChief Scientific OfficerSale4,100$2.60$10.7KForm 4
Dec 22, 2025Moreadith RandallChief Scientific OfficerSale5,673$2.67$15.1KForm 4
Dec 16, 2025Moreadith RandallChief Scientific OfficerSale3,227$2.96$9.6KForm 4

All 71 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 26. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Sio Capital Management, LLC1,000,000$1.9M0.3%No change
Vanguard Capital Management LLC162,198$314.7K0.0%+3,062
Waverly Advisors, LLC67,492$130.9K0.0%No change
Geode Capital Management, LLC51,007$99.0K0.0%−13,966
Keel Point, LLC21,508$41.7K0.0%No change
Northern Trust Corp20,771$40.3K0.0%New
Vanguard Fiduciary Trust Co20,009$38.8K0.0%No change
Avidian Wealth Enterprises, LLC18,800$36.5K0.0%No change
Jane Street Group, LLC15,444$30.0K0.0%−24,209
State Street Corp12,758$24.8K0.0%No change
Caitong International Asset Management Co., Ltd3,744$7.3K0.0%−238
Wells Fargo & Company/mn3,611$7.0K0.0%+5
Tower Research Capital LLC (TRC)2,570$5.0K0.0%+1,727
BlackRock, Inc.2,378$4.6K0.0%−55,886
Osaic Holdings, Inc.2,002$3.9K0.0%+1,001
UBS Group AG1,347$2.6K0.0%+1,342
Barclays PLC545$1.1K0.0%New
Piscataqua Savings Bank28$540.0%No change
Morgan Stanley14$280.0%+6
Albion Financial Group /ut8$160.0%No change
Pacifica Partners Inc.8$150.0%No change
Bnp Paribas Financial Markets2$40.0%No change
Rockefeller Capital Management L.P.2$40.0%No change
Jpmorgan Chase & Co1$20.0%New
Global Retirement Partners, LLC1$20.0%New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41